Cat. No.: DAB-0012791
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide surrounding Asn60 of human REDD1. Antibodies are purified by peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | DDIT4 |
| UniProt No. | Q9NX09 |
| Gene ID | 54541 |
| Gene Description | REDD1 expression is induced by hypoxia, cell stress, apoptosis and DNA damage. REDD1 is a transcriptional target of p53 and p63 following DNA damage, and links p63 to Ros. REDD1 functions as a negative regulator of mTOR in response to hypoxia in a tuberin-dependent manner. Depending on cell context, REDD1 can either be protecting or detrimental for cells under oxidative or ischemic stresses. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
